Assessing changes in colonic physiology in IBS-C patients treated with Linaclotide 

Study objective

Linaclotide is an approved treatment for IBS-C, but its physiological effects on the human gastrointestinal tract are not fully understood. This study aimed to investigate how linaclotide affects cecal pH, colonic transit, and motility, and how these physiological changes relate to symptom improvement and quality of life in IBS-C patients.

How does it address a real-world gut health problem?

IBS-C is a common and challenging condition with limited treatment options that address both symptoms and underlying motility issues. Understanding linaclotide’s mechanism of action can help clinicians better target therapy and predict patient response, especially in those with altered colonic fermentation or motility.

Study design

Type of trial: Prospective, single-arm trial

Sample size and population: 13 adults meeting Rome III criteria for IBS-C

Duration and intervention:

  • Baseline assessment using wireless motility capsule (WMC) and validated symptom questionnaires

  • 28-day treatment with linaclotide 290 µg once daily

  • Repeat WMC and questionnaires post-treatment

Endpoints

Primary outcome:

  • Change in pH across the ileocecal junction (ICJ), indicating cecal fermentation

  • Colonic transit time and motility index via WMC

Secondary outcomes:

  • Stool consistency (Bristol Stool Form Scale)

  • Frequency of spontaneous bowel movements (SBM)

  • Gastrointestinal symptom intensity and unpleasantness

  • Visceral sensitivity index

  • Quality of life scores

Results

  • Reduced microbial fermentation in the cecum: A modest increase in cecal pH was observed following linaclotide administration, indicating a reduction in microbial fermentation activity. This shift may contribute to decreased gas production and alleviation of bloating symptoms.

  • Enhanced colonic transit: Linaclotide significantly accelerated the passage of luminal contents through the colon, reflecting improved gastrointestinal motility. This effect is consistent with its clinical utility in relieving constipation in IBS-C patients.

  • Increased colonic contractile activity: Treatment with linaclotide resulted in a higher colonic motility index, suggesting more frequent and forceful muscular contractions. This enhancement in colonic motor function supports more efficient propulsion of intestinal contents.

Commercial relevance

How the findings support product claims:

This study provides mechanistic evidence that linaclotide’s therapeutic effects in IBS-C are linked to its ability to modulate colonic pH and motility. These findings support its use not only for symptom relief but also for improving underlying physiological dysfunction in IBS-C, reinforcing its value in clinical practice.

© Copyright The Functional Gut Group 2026